This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (183)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

The Swiss Heart Study: A Randomized Controlled Trial

Guido Schnyder, MD; Marco Roffi, MD; Yvonne Flammer, MD; Riccardo Pin, MD; Otto Martin Hess, MD

JAMA. 2002;288:973-979.

Context  Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after percutaneous coronary intervention.

Objective  To evaluate the effect of homocysteine-lowering therapy on clinical outcome after percutaneous coronary intervention.

Design, Setting, and Participants  Randomized, double-blind placebo-controlled trial involving 553 patients referred to the University Hospital in Bern, Switzerland, from May 1998 to April 1999 and enrolled after successful angioplasty of at least 1 significant coronary stenosis (50%).

Intervention  Participants were randomly assigned to receive a combination of folic acid (1 mg/d), vitamin B₁₂ (cyanocobalamin, 400 µg/d), and vitamin B₆ (pyridoxine hydrochloride, 10 mg/d) (n = 272) or placebo (n = 281) for 6 months.

Main Outcome Measure  Composite end point of major adverse events defined as death, nonfatal myocardial infarction, and need for repeat revascularization, evaluated at 6 months and 1 year.

Results  After a mean (SD) follow-up of 11 (3) months, the composite end point was significantly lower at 1 year in patients treated with homocysteine-lowering therapy (15.4% vs 22.8%; relative risk [RR], 0.68; 95% confidence interval [CI], 0.48-0.96; P = .03), primarily due to a reduced rate of target lesion revascularization (9.9% vs 16.0%; RR, 0.62; 95% CI, 0.40-0.97; P = .03). A nonsignificant trend was seen toward fewer deaths (1.5% vs 2.8%; RR, 0.54; 95% CI, 0.16-1.70; P = .27) and nonfatal myocardial infarctions (2.6% vs 4.3%; RR, 0.60; 95% CI, 0.24-1.51; P = .27) with homocysteine-lowering therapy. These findings remained unchanged after adjustment for potential confounders.

Conclusion  Homocysteine-lowering therapy with folic acid, vitamin B₁₂, and vitamin B₆ significantly decreases the incidence of major adverse events after percutaneous coronary intervention.

Author Affiliations: Division of Cardiology, Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland (Drs Flammer, Pin, and Hess); Department of Cardiovascular Medicine/F25, The Cleveland Clinic Foundation, Cleveland, Ohio (Dr Roffi); and the Division of Cardiology, UCSD Medical Center, University of California, San Diego (Dr Schnyder).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Homocysteine and Pulsatility Index of Cerebral Arteries
Lim et al.
Stroke 2009;40:3216-3220.
ABSTRACT | FULL TEXT  

Micronutrient Supplementation in Adult Nutrition Therapy: Practical Considerations
Sriram and Lonchyna
JPEN J Parenter Enteral Nutr 2009;33:548-562.
ABSTRACT | FULL TEXT  

Plasma Vitamin B6 and Risk of Myocardial Infarction in Women
Page et al.
Circulation 2009;120:649-655.
ABSTRACT | FULL TEXT  

Nutrient supplements and cardiovascular disease: a heartbreaking story
Lichtenstein
J. Lipid Res. 2009;50:S429-S433.
ABSTRACT | FULL TEXT  

Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women: The Women's Antioxidant and Folic Acid Cardiovascular Study
Christen et al.
Arch Intern Med 2009;169:335-341.
ABSTRACT | FULL TEXT  

Folic Acid-Based Intervention in Non-ST Elevation Acute Coronary Syndromes
Imasa et al.
Asian Cardiovasc. Thorac. Ann. 2009;17:13-21.
ABSTRACT | FULL TEXT  

A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease
Kang et al.
Am. J. Clin. Nutr. 2008;88:1602-1610.
ABSTRACT | FULL TEXT  

Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial
Ebbing et al.
JAMA 2008;300:795-804.
ABSTRACT | FULL TEXT  

Is folic acid good for everyone?
Smith et al.
Am. J. Clin. Nutr. 2008;87:517-533.
ABSTRACT | FULL TEXT  

Homocysteine and cardiovascular disease: a review of the evidence
Wierzbicki
Diabetes and Vascular Disease Research 2007;4:143-149.
ABSTRACT  

Effect of Folic Acid Supplementation on Risk of Cardiovascular Diseases: A Meta-analysis of Randomized Controlled Trials
Bazzano et al.
JAMA 2006;296:2720-2726.
ABSTRACT | FULL TEXT  

Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease: Not Validated
Kaul et al.
J Am Coll Cardiol 2006;48:914-923.
ABSTRACT | FULL TEXT  

Obese Children and Adolescents: A Risk Group for Low Vitamin B12 Concentration.
Pinhas-Hamiel et al.
Arch Pediatr Adolesc Med 2006;160:933-936.
ABSTRACT | FULL TEXT  

The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease
Refsum et al.
J. Nutr. 2006;136:1731S-1740S.
ABSTRACT | FULL TEXT  

Dietary choline and betaine assessed by food-frequency questionnaire in relation to plasma total homocysteine concentration in the Framingham Offspring Study.
Cho et al.
Am. J. Clin. Nutr. 2006;83:905-911.
ABSTRACT | FULL TEXT  

Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure: A Multicenter, Randomized, Controlled Trial
Zoungas et al.
J Am Coll Cardiol 2006;47:1108-1116.
ABSTRACT | FULL TEXT  

PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting
Marcucci et al.
Heart 2006;92:377-381.
ABSTRACT | FULL TEXT  

Homocysteine: Call Off the Funeral
Spence
Stroke 2006;37:282-283.
FULL TEXT  

Vitamin Intervention for Stroke Prevention Trial: An Efficacy Analysis
Spence et al.
Stroke 2005;36:2404-2409.
ABSTRACT | FULL TEXT  

A B12-responsive Internal Ribosome Entry Site (IRES) Element in Human Methionine Synthase
Oltean and Banerjee
J. Biol. Chem. 2005;280:32662-32668.
ABSTRACT | FULL TEXT  

Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine)
Vogel et al.
J Am Coll Cardiol 2005;46:184-221.
FULL TEXT  

Effect of Lowering of Homocysteine Levels on Inflammatory Markers: A Randomized Controlled Trial
Durga et al.
Arch Intern Med 2005;165:1388-1394.
ABSTRACT | FULL TEXT  

B vitamins and cognitive function: do we need more and larger trials?
Vollset and Ueland
Am. J. Clin. Nutr. 2005;81:951-952.
FULL TEXT  

Hyperhomocysteinemic Diabetic Cardiomyopathy: Oxidative Stress, Remodeling, and Endothelial-Myocyte Uncoupling
Tyagi et al.
J CARDIOVASC PHARMACOL THER 2005;10:1-10.
ABSTRACT  

Lack of association between baseline plasma homocysteine concentrations and restenosis rates after a first elective percutaneous coronary intervention without stenting
Wong et al.
Heart 2004;90:1299-1302.
ABSTRACT | FULL TEXT  

Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy?
Postuma and Lang
Neurology 2004;63:886-891.
ABSTRACT | FULL TEXT  

Folic Acid-Based Multivitamin Therapy to Prevent Stroke: The Jury Is Still Out
Hankey and Eikelboom
Stroke 2004;35:1995-1998.
FULL TEXT  

Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk
Friso et al.
Am. J. Clin. Nutr. 2004;79:992-998.
ABSTRACT | FULL TEXT  

Homocysteine Enhances Endothelial Apoptosis via Upregulation of Fas-Mediated Pathways
Suhara et al.
Hypertension 2004;43:1208-1213.
ABSTRACT | FULL TEXT  

Is there a need for novel cardiovascular risk factors?
von Eckardstein
Nephrol Dial Transplant 2004;19:761-765.
FULL TEXT  

Effect of Experimental Hyperhomocysteinemia on Cardiac Structure and Function in the Rat
Walker et al.
Annals of Clinical & Laboratory Science 2004;34:175-180.
ABSTRACT | FULL TEXT  

Serum Homocysteine in Relation to Mortality and Morbidity From Coronary Heart Disease: A 24-Year Follow-Up of the Population Study of Women in Gothenburg
Zylberstein et al.
Circulation 2004;109:601-606.
ABSTRACT | FULL TEXT  

Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial
Toole et al.
JAMA 2004;291:565-575.
ABSTRACT | FULL TEXT  

The Challenge of Stroke Prevention
Hanley
JAMA 2004;291:621-622.
FULL TEXT  

High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention
Takamori et al.
Circulation 2004;109:481-486.
ABSTRACT | FULL TEXT  

Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Fonseca et al.
Endocr. Rev. 2004;25:153-175.
ABSTRACT | FULL TEXT  

Renal Disease, Homocysteine, and Cardiovascular Complications
Robinson
Circulation 2004;109:294-295.
FULL TEXT  

Management of Glomerular Proteinuria: A Commentary
Wilmer et al.
J. Am. Soc. Nephrol. 2003;14:3217-3232.
ABSTRACT | FULL TEXT  

Low Dose Betaine Supplementation Leads to Immediate and Long Term Lowering of Plasma Homocysteine in Healthy Men and Women
Olthof et al.
J. Nutr. 2003;133:4135-4138.
ABSTRACT | FULL TEXT  

Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
Hackam and Anand
JAMA 2003;290:932-940.
ABSTRACT | FULL TEXT  

Multivitamin Supplements Are Inversely Associated with Risk of Myocardial Infarction in Men and Women--Stockholm Heart Epidemiology Program (SHEEP)
Holmquist et al.
J. Nutr. 2003;133:2650-2654.
ABSTRACT | FULL TEXT  

Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation
Sasaki et al.
J Am Coll Cardiol 2003;42:364-372.
ABSTRACT | FULL TEXT  

Folic Acid Supplements and Fortification Affect the Risk for Neural Tube Defects, Vascular Disease and Cancer: Evolving Science,
Bailey et al.
J. Nutr. 2003;133:1961S-1968.
ABSTRACT | FULL TEXT  

Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study
van Oort et al.
Am. J. Clin. Nutr. 2003;77:1318-1323.
ABSTRACT | FULL TEXT  

News and Views on Folate and Elderly Persons
Lokk
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2003;58:M354-361.
ABSTRACT | FULL TEXT  

A Role for Multivitamins in Infection?
Fawzi and Stampfer
ANN INTERN MED 2003;138:430-431.
FULL TEXT  

Homocysteine lowering treatment improved outcomes after percutaneous coronary intervention
Eikelboom
Evid. Based Med. 2003;8:48-48.
FULL TEXT  

'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?
Davey Smith and Ebrahim
Int J Epidemiol 2003;32:1-22.
ABSTRACT | FULL TEXT  

Elevated Plasma Homocysteine Levels in Patients Treated With Levodopa: Association With Vascular Disease
Rogers et al.
Arch Neurol 2003;60:59-64.
ABSTRACT | FULL TEXT  

JournalScan
Malik
Heart 2002;88:551-552.
FULL TEXT  

Optimal Diets for Prevention of Coronary Heart Disease
Hu and Willett
JAMA 2002;288:2569-2578.
ABSTRACT | FULL TEXT  

Homocysteine and Coronary Heart Disease: How Great Is the Hazard?
Wilson
JAMA 2002;288:2042-2043.
FULL TEXT  

Folate Treatment Linked with Lower 1-Year TLR Rates After Angioplasty
Journal Watch Cardiology 2002;2002:2-2.
FULL TEXT  

Therapy with Folate and Vitamins B12 and B6 After Coronary Angioplasty
JWatch General 2002;2002:1-1.
FULL TEXT